Sanofi’s Acquisition of Dynavax Nears Final Approval
Published on 02/02/2026 at 09:11 | Redaktion boerse-global.de
A key regulatory obstacle has been cleared for Sanofi’s planned $2.2 billion purchase of Dynavax Technologies, moving the major pharmaceutical deal closer to completion. The transaction, aimed at bolstering the French giant’s standing in the adult vaccine market, recently received a crucial green light from German investment control authorities.
Sanofi first announced its intention to acquire Dynavax in late 2025. The agreement involves a cash payment of $15.50 per share, a figure that represented a significant premium to the market price at the time of the deal’s announcement. With the latest regulatory approval secured on January 29, 2026, the parties are targeting a final closing within the first quarter of 2026.
Market sentiment Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
